“World’s largest book sale” comes to Middle East at giant hangar in Dubai

A visitor reads a book at the Big Bad Wolf Book Sale, which calls itself the world's biggest, hosted for the first time by Dubai, UAE October 17, 2018. Picture taken October 17, 2018. (Reuters)
Updated 18 October 2018
0

“World’s largest book sale” comes to Middle East at giant hangar in Dubai

  • The Big Bad Wolf Book Sale, launched in Kuala Lumpur in 2009, has since regularly toured Asian cities
  • Organizers hope to attract as many as 300,000 visitors during 11 days in Dubai
DUBAI: A gargantuan touring book sale that touts itself as the world’s largest is making its first stop in the Middle East, filling a huge hangar in Dubai with stacks of 3 million discounted books, open around the clock.
The Big Bad Wolf Book Sale, launched in Kuala Lumpur in 2009, has since regularly toured Asian cities including Jakarta, Manila, Cebu, Colombo, Bangkok and Taipei. Organizers hope to attract as many as 300,000 visitors during 11 days in Dubai.
Founder Andrew Yap said he expects the sheer number of books will lure in punters.
“In a mature market like Dubai, this will give variety to readers,” he told Reuters.
Roudha Al Marri, an Emirati co-author of a guide to life in the UAE whose own book was on sale at the fair, said a city such as Dubai needed such an event to help spur reading among a “tablet generation” preoccupied with screens.
“To hold a book, smell it, to return us to more beautiful days, to throw us into mazes of stories. Every generation needs this,” she said.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”